Clinical trial
Randomized Phase III Trial of Neoadjuvant Immunotherapy With Response-Adapted Treatment Versus Standard-of-Care Treatment for Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma (C-PRE)
NCT06568172 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized Phase III Trial of Neoadjuvant Immunotherapy With Response-Adapted Treatment Versus Standard-of-Care Treatment for Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma (C-PRE)
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 3
- Overall status
- Suspended
- Start date
- February 18, 2025
- Completion date
- August 14, 2031
- Enrollment
- 420 (estimated)
- Sites
- 206
Conditions
As the registry lists them; a condition with its own page is linked.
eyelid squamous cell carcinoma, recurrent eyelid squamous cell carcinoma, recurrent skin acantholytic squamous cell carcinoma, recurrent skin clear cell squamous cell carcinoma, recurrent skin lymphoepithelial carcinoma, recurrent skin spindle cell squamous cell carcinoma, recurrent skin squamous cell carcinoma with sarcomatoid differentiation, resectable eyelid squamous cell carcinoma, resectable skin acantholytic squamous cell carcinoma, resectable skin clear cell squamous cell carcinoma, resectable skin lymphoepithelial carcinoma, resectable skin spindle cell squamous cell carcinoma, resectable skin squamous cell carcinoma with sarcomatoid differentiation, skin acantholytic squamous cell carcinoma, skin clear cell squamous cell carcinoma, skin lymphoepithelial carcinoma, skin spindle cell squamous cell carcinoma, skin squamous cell carcinoma with sarcomatoid differentiation, stage iii head and neck cutaneous squamous cell carcinoma ajcc v8, stage iv head and neck cutaneous squamous cell carcinoma ajcc v8